
We report a summary of a Phase I clinical trial of the partially zzso zzso zzso of zzso human zzso zzso zzso conducted in 39 patients with advanced zzso The trial was conducted in four zzso two subcutaneous and two intravenous routes and schedules of zzso zzso limiting toxicity in the subcutaneous trials was volume zzso The intravenous trial was remarkably well tolerated so that the maximum tolerable dose exceeded zzso The study demonstrated modification of the immune system including an increase in skin test zzso an increase in absolute zzso counts, zzso in the zzso zzso zzso zzso and an increase in zzso zzso zzso in the intravenous trial was limited to transient zzso reactions that were ameliorated by increasing the infusion zzso Three objective tumor responses were zzso 

